Fundraising FoxTarnagulla Ventures
Venture capitalMelbourne · Seed–Series A · 2 people tracked
Find your way into Tarnagulla Ventures
Sign up to see every warm intro you have to Tarnagulla Ventures
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Tarnagulla Ventures team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
Tarnagulla Ventures is an exclusively life science and healthcare investor, providing seed and early-stage venture capital to promising companies. It follows a concentrated, low-frequency investment approach, favoring fewer but deeper commitments so it can dedicate significant time to nurturing portfolio companies with strategic support. Beyond financial capital, the firm emphasizes contributing intellectual capital drawn from its experience in small molecule, protein, and cell-based therapeutics. As value investors, it treats the initial investment as the beginning of a long-term partnership. Although headquartered in Melbourne, Australia, most of its investments are in US-based companies, and it focuses on bringing medical technology to Australian and US markets.
Source: firm website, verified Aug 3, 2026.
Team · 2 people
from the firm's website
What they invest in
from 6 of 8 portfolio companiesBiotech ×5Healthtech ×4Digital Health ×2Medical Devices ×2
HQs:United States×4
Investments · 8 tracked
founders shown can be your intro pathJupiter Neurosciences is a biopharmaceutical company developing JOTROL, a patented micellar oral formulation of resveratrol designed to cross the blood-brain barrier for central nervous system treatment.
BiotechDigital Health
Christer Rosén(Chairman of Board, Chief Executive Officer and Director)inMarshall Hayward(Chief Scientific Officer and Director)Alison D. Silva(President and Chief Operating Officer, and Director)Alexander Rosén(Chief Administrative Officer)in
Jupiter Neurosciences develops JOTROL, an enhanced resveratrol formulation designed to address neuroinflammatory and central nervous system disorders, with a Phase IIa trial underway in Parkinson's Disease, while also selling wellness supplements under the Nugevia brand through direct-to-consumer channels.
HealthtechJupiter, US
Jacob Uittenbogaard(Chief Financial Officer, Treasurer and Secretary)inMarshall Hayward(Chief Scientific Officer)Christer Rosén(Chief Executive Officer and President)inSaleem Elmasri(Chief Financial Officer)Alexander Rosén(Chief Administrative Officer)inAlison D. Silva(President and Chief Operating Officer, and Director)
A clinical-stage biopharmaceutical company developing small molecule therapies for schizophrenia, bipolar depression, and other neuropsychiatric disorders.
BiotechHealthtechNew York, US
Zachary Prensky(Executive Officer, Director)inLauren Stipp(Executive Officer)Mark Panoff(Executive Officer)Heather Turner(President & Chief Executive Officer and Director)Gad Soffer(Chief Operating and Business Officer)Anna Eramo(Chief Medical Officer)
Co-investorsPivotal Life SciencesPontifax Venture CapitalVida VenturesTCG Crossover
Clinical-stage biopharmaceutical company developing best-in-class aryl hydrocarbon receptor agonists.
BiotechEncino, US
Matthew Davidson(Executive Officer, Director)
BoardDennis Brown(Director)
Co-investors7G BioVentures
Portfolio company acquired by Novo Nordisk for $1.1B USD.
Co-investorsAmorChemGenesys CapitalJDRF T1D FundNew Enterprise Associates (NEA)adMare BioInnovationsAmgen Ventures+2 more
Lubricin (PRG4) is a glycoprotein found naturally in the human body that lubricates and protects tissue surfaces from friction and wear.
BiotechHealthtechMedical Devices
Co-investorsThynk Capital
Based on the page listing "Ophthalmic Pharmaceutical Consultant" and "Chief Clinical Officer" roles, Nacuity appears to be a pharmaceutical company focused on ophthalmology (eye care), though the page provides insufficient detail to confirm products, customer base, or market focus.
BiotechDigital HealthHealthtechMedical DevicesFort Worth, US
Michael Wall(Executive Officer)inDavid Wohlberg(Executive Officer, Director)Jami Kern(Executive Officer)inHalden Conner(Executive Officer, Director)inCharles Lieser(Executive Officer)Carol Lakkis(Director/R&D Technical Director)in
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Prevatex
Exits · 4
3 IPOs · 1 acquisitionsJupiter Neurosciences, Inc.NASDAQ: JUNSJupiter Orphan TherapeuticsNASDAQ: JUNSLB PharmaceuticalsNASDAQ: LBRXInversagoacq. by Novo Nordisk
Portfolio news
latest coverage across their companiesAzora Therapeutics · globenewswire.com · Jun 11, 2026
Jupiter Neurosciences, Inc. · finance.yahoo.com · Mar 2, 2026
Frequently asked questions
- How many investments has Tarnagulla Ventures made?
- Tarnagulla Ventures has 8 tracked investments, 4 of which have exited.
- What stage does Tarnagulla Ventures invest at?
- Tarnagulla Ventures invests at the Seed, Series A stages.
- What sectors does Tarnagulla Ventures focus on?
- Tarnagulla Ventures focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is Tarnagulla Ventures located?
- Tarnagulla Ventures is headquartered in Melbourne, AU.
- Who does Tarnagulla Ventures co-invest with?
- Tarnagulla Ventures most often shares deals with Genesys Capital, JDRF T1D Fund, New Enterprise Associates (NEA), among 9 tracked co-investors.
Similar investors
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests in technology companies from seed to growth stage. Since inception it has backed over 200 companies and raised more than $1.3 billion.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Breyer Capital is a venture capital firm that backs high-impact entrepreneurs, making strategic investments guided by founder passion and its network of experienced investors.
Canaan Partners is a venture capital firm with over 30 years of history, backing companies across technology and healthcare sectors through close, hands-on partnerships with founders.
Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.